STAMBP and neoplasm: Treatment of mice with s.c. M21 tumours with 18.5 or 37 MBq of [177Lu]Lu-DOTA-α-MSH-NPs administered i.v. increased median survival to 58 and 43 d, respectively, compared to mice treated with non-radiolabeled NPs (41 d) or no treatment (27 d).